| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CPT.169 |
| P698 | PubMed publication ID | 26073179 |
| P50 | author | Chie Emoto | Q60696921 |
| Alexander Vinks | Q77512299 | ||
| P2093 | author name string | T Fukuda | |
| P2860 | cites work | Asthma across the ages: knowledge gaps in childhood asthma | Q26821787 |
| Forecasting individual pharmacokinetics | Q28244326 | ||
| Proposals for model-based paediatric medicinal development within the current European Union regulatory framework | Q28749999 | ||
| Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data | Q30666721 | ||
| Dashboard systems: implementing pharmacometrics from bench to bedside | Q38221759 | ||
| Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies | Q38364464 | ||
| Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice | Q39870288 | ||
| Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals | Q40869150 | ||
| Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity | Q41368460 | ||
| Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug | Q41975490 | ||
| Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model | Q42919793 | ||
| A model-based approach to dose selection in early pediatric development | Q43182469 | ||
| Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants | Q43663687 | ||
| Therapeutic drug monitoring as a component of personalized medicine: applications in pediatric drug development | Q44131969 | ||
| Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate | Q44140105 | ||
| Predictive performance of a physiologically based pharmacokinetic model of busulfan in children | Q44419087 | ||
| Pediatric drug labeling: improving the safety and efficacy of pediatric therapies | Q44556060 | ||
| Dosing rationale for fixed-dose combinations in children: shooting from the hip? | Q44677507 | ||
| Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. | Q44797030 | ||
| Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies | Q47338503 | ||
| The randomized concentration-controlled trial: An evaluation of its sample size efficiency | Q47422264 | ||
| A physiologically based pharmacokinetic model for Valproic acid in adults and children | Q48667029 | ||
| Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate | Q50476254 | ||
| Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. | Q51796989 | ||
| Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. | Q51912479 | ||
| Development and evaluation of a generic physiologically based pharmacokinetic model for children. | Q51933198 | ||
| A mechanistic approach for the scaling of clearance in children. | Q52013911 | ||
| Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition. | Q54455016 | ||
| A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children | Q57730442 | ||
| Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model | Q83940718 | ||
| Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics | Q84114993 | ||
| Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome | Q84762635 | ||
| Fostering Culture and Optimizing Organizational Structure for Implementing Model‐Based Drug Development | Q85111384 | ||
| Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach | Q86716291 | ||
| A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children | Q87426780 | ||
| Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents | Q30832465 | ||
| Tips and traps analyzing pediatric PK data. | Q33820152 | ||
| Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children | Q33998916 | ||
| Extrapolation of adult data and other data in pediatric drug-development programs | Q34057100 | ||
| What is the right dose for children? | Q34180493 | ||
| Developmental pharmacology--drug disposition, action, and therapy in infants and children | Q34247047 | ||
| Bridging the gap: a review of dose investigations in paediatric investigation plans | Q34554486 | ||
| Physiologically based pharmacokinetic modeling and simulation in pediatric drug development | Q34658074 | ||
| Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants. | Q35179536 | ||
| Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents | Q35624622 | ||
| Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group | Q35667919 | ||
| Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs | Q35827012 | ||
| Sample size calculation for the proportional hazards cure model | Q36420144 | ||
| Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy | Q36478646 | ||
| Population clinical pharmacology of children: modelling covariate effects. | Q36522932 | ||
| Population clinical pharmacology of children: general principles. | Q36522936 | ||
| Model-based drug development | Q36830686 | ||
| Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. | Q36865546 | ||
| A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam | Q36910537 | ||
| Mechanism-based concepts of size and maturity in pharmacokinetics | Q36960112 | ||
| Facilitation of drug evaluation in children by population methods and modelling | Q37108169 | ||
| Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings | Q37149100 | ||
| Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children | Q37279407 | ||
| Mechanistic basis of using body size and maturation to predict clearance in humans | Q37404427 | ||
| A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn | Q37404434 | ||
| Pediatric antihypertensive trial failures: analysis of end points and dose range | Q37436147 | ||
| The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. | Q37521422 | ||
| Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician | Q37692028 | ||
| Pediatric dose selection | Q37693681 | ||
| Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science | Q37790383 | ||
| Advances in paediatric pharmacokinetics | Q37813680 | ||
| Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review | Q37824590 | ||
| Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. | Q37978192 | ||
| Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings | Q38187000 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 298-308 | |
| P577 | publication date | 2015-06-13 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children | |
| P478 | volume | 98 |
| Q100388434 | A model averaging/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study |
| Q47183620 | A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants |
| Q92519343 | Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients |
| Q50045460 | Bridging Adult Experience to Pediatrics in Oncology Drug Development |
| Q38853020 | Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development. |
| Q49577175 | Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation |
| Q37660713 | Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter. |
| Q85373768 | Children: Are We Doing Enough? |
| Q38958562 | Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents |
| Q38879907 | Design and conduct of early phase drug studies in children: challenges and opportunities |
| Q47781069 | Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status |
| Q48287062 | Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy |
| Q47222670 | Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach |
| Q36828605 | Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease |
| Q64042976 | Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children |
| Q50465181 | Medicines for Pediatric Patients-Biopharmaceutical, Developmental, and Regulatory Considerations |
| Q55470248 | Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status. |
| Q87037985 | Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care |
| Q61847182 | PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants |
| Q52575612 | Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. |
| Q40544137 | Population pharmacokinetics of thrombomodulin alfa in pediatric patients with hematological malignancy and disseminated intravascular coagulation |
| Q50062507 | Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children |
| Q37283027 | Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children |
| Q38808391 | Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling |
| Q88734028 | State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development |
| Q91482243 | The World Health Organization Prequalification Program and Clinical Pharmacology in 2030 |
| Q89993148 | Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development |
| Q38602911 | Treating children with inflammatory bowel disease: Current and new perspectives |
| Q62086883 | Update of the Scientific Opinion on opium alkaloids in poppy seeds |
| Q55360869 | Useful pharmacodynamic endpoints in children: selection, measurement, and next steps. |
Search more.